10x Genomics Inc

None of our directors or officers adopted, modified orterminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement during the quarter ended March 31, 2024, as such terms are defined under Item 408(a) of Regulation S-K, except as follows:

On December 13, 2023, James L. Wilbur, our former Chief Commercial Officer, adopted a Rule 10b5-1 trading arrangement that was intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 147,095 shares of the Company’s common stock. The expiration date of the trading arrangement was December 31, 2024. On February 21, 2024, the trading arrangement wasterminated at the election of Dr. Wilbur.

On March 10, 2024, Shehnaaz Suliman, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 20,016 shares of the Company’s common stock. The expiration date of the trading arrangement is June 14, 2024.

On March 11, 2024, Benjamin J. Hindson, Chief Scientific Officer and President, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 22,496 shares of the Company’s common stock plus up to 190,845 carryover shares from a prior 10b5-1 plan that will expire on June 14, 2024, subject to certain conditions. The expiration date of the trading arrangement is June 13, 2025.